50 related articles for article (PubMed ID: 37551485)
1. [Construction of a Mouse Model for Myeloproliferative Neoplasms and an Evaluation System].
Wang SJ; Yu XR; Zhang QG; Li YJ; Fu CL; Xu KL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Aug; 31(4):1113-1118. PubMed ID: 37551485
[TBL] [Abstract][Full Text] [Related]
2. Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
Pomicter AD; Eiring AM; Senina AV; Zabriskie MS; Marvin JE; Prchal JT; O'Hare T; Deininger MW
Exp Hematol; 2015 Jul; 43(7):537-45.e1-11. PubMed ID: 25912019
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia.
Haage TR; Charakopoulos E; Bhuria V; Baldauf CK; Korthals M; Handschuh J; Müller P; Li J; Harit K; Nishanth G; Frey S; Böttcher M; Fischer KD; Dudeck J; Dudeck A; Lipka DB; Schraven B; Green AR; Müller AJ; Mougiakakos D; Fischer T
J Hematol Oncol; 2024 Jun; 17(1):43. PubMed ID: 38853260
[TBL] [Abstract][Full Text] [Related]
4. SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm.
Yang Y; Abbas S; Sayem MA; Dutta A; Mohi G
Blood Cancer J; 2023 Nov; 13(1):171. PubMed ID: 38012156
[TBL] [Abstract][Full Text] [Related]
5. IL-1β promotes MPN disease initiation by favoring early clonal expansion of JAK2-mutant hematopoietic stem cells.
Rai S; Zhang Y; Grockowiak E; Kimmerlin Q; Hansen N; Stoll CB; Usart M; Luque Paz D; Hao-Shen H; Zhu Y; Roux J; Bader MS; Dirnhofer S; Farady CJ; Schroeder T; Méndez-Ferrer S; Skoda RC
Blood Adv; 2024 Mar; 8(5):1234-1249. PubMed ID: 38207211
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of PAK1 generates an ameliorative effect on MPLW515L mouse model of myeloproliferative neoplasms by regulating the differentiation and survival of megakaryocytes.
Fu C; Hu X; Wang S; Yu X; Zhang Q; Zhang L; Qi K; Li Z; Xu K
Exp Hematol; 2023 Nov; 127():59-69.e2. PubMed ID: 37741606
[TBL] [Abstract][Full Text] [Related]
7. Identification of curaxin as a potential new therapeutic for JAK2 V617F mutant patients.
Pearson S; Blance R; Yan F; Hsieh YC; Geary B; Amaral FMR; Somervaille TCP; Kirschner K; Whetton AD; Pierce A
PLoS One; 2023; 18(5):e0286412. PubMed ID: 37253035
[TBL] [Abstract][Full Text] [Related]
8. Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms.
Usart M; Stetka J; Luque Paz D; Hansen N; Kimmerlin Q; Almeida Fonseca T; Lock M; Kubovcakova L; Karjalainen R; Hao-Shen H; Börsch A; El Taher A; Schulz J; Leroux JC; Dirnhofer S; Skoda RC
Blood; 2024 Jun; 143(24):2490-2503. PubMed ID: 38493481
[TBL] [Abstract][Full Text] [Related]
9. Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable.
Codilupi T; Szybinski J; Arunasalam S; Jungius S; Dunbar AC; Stivala S; Brkic S; Albrecht C; Vokalova L; Yang JL; Buczak K; Ghosh N; Passweg JR; Rovo A; Angelillo-Scherrer A; Pankov D; Dirnhofer S; Levine RL; Koche R; Meyer SC
Clin Cancer Res; 2024 Feb; 30(3):586-599. PubMed ID: 37992313
[TBL] [Abstract][Full Text] [Related]
10. CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis.
Dunbar AJ; Kim D; Lu M; Farina M; Bowman RL; Yang JL; Park Y; Karzai A; Xiao W; Zaroogian Z; O'Connor K; Mowla S; Gobbo F; Verachi P; Martelli F; Sarli G; Xia L; Elmansy N; Kleppe M; Chen Z; Xiao Y; McGovern E; Snyder J; Krishnan A; Hill C; Cordner K; Zouak A; Salama ME; Yohai J; Tucker E; Chen J; Zhou J; McConnell T; Migliaccio AR; Koche R; Rampal R; Fan R; Levine RL; Hoffman R
Blood; 2023 May; 141(20):2508-2519. PubMed ID: 36800567
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow.
Holmström MO; Andersen M; Traynor S; Ahmad SM; Lisle TL; Handlos Grauslund J; Skov V; Kjær L; Ottesen JT; Gjerstorff MF; Hasselbalch HC; Andersen MH
Front Immunol; 2023; 14():1240678. PubMed ID: 37662956
[TBL] [Abstract][Full Text] [Related]
12. Variability of bone marrow biopsy reporting affects accuracy of diagnosis of myeloproliferative neoplasms: data from the ALLG MPN01 registry.
Ng WY; Erber WN; Grigg A; Dunne K; Perkins A; Forsyth C; Ross DM
Pathology; 2024 Feb; 56(1):75-80. PubMed ID: 38071156
[TBL] [Abstract][Full Text] [Related]
13. LKB1/
Marinaccio C; Suraneni P; Celik H; Volk A; Wen QJ; Ling T; Bulic M; Lasho T; Koche RP; Famulare CA; Farnoud N; Stein B; Schieber M; Gurbuxani S; Root DE; Younger ST; Hoffman R; Gangat N; Ntziachristos P; Chandel NS; Levine RL; Rampal RK; Challen GA; Tefferi A; Crispino JD
Cancer Discov; 2021 Jun; 11(6):1398-1410. PubMed ID: 33579786
[TBL] [Abstract][Full Text] [Related]
14. Quantitative interpretation of bone marrow biopsies in MPN-What's the point in a molecular age?
Ryou H; Lomas O; Theissen H; Thomas E; Rittscher J; Royston D
Br J Haematol; 2023 Nov; 203(4):523-535. PubMed ID: 37858962
[TBL] [Abstract][Full Text] [Related]
15. Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms.
Holmström MO; Hasselbalch HC; Andersen MH
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630667
[TBL] [Abstract][Full Text] [Related]
16. Increased CXCL10 (IP-10) is associated with advanced myeloproliferative neoplasms and its loss dampens erythrocytosis in mouse models.
Belmonte M; Cabrera-Cosme L; Øbro NF; Li J; Grinfeld J; Milek J; Bennett E; Irvine M; Shepherd MS; Cull AH; Boyd G; Riedel LM; Chi Che JL; Oedekoven CA; Baxter EJ; Green AR; Barlow JL; Kent DG
Exp Hematol; 2024 May; ():104246. PubMed ID: 38763471
[TBL] [Abstract][Full Text] [Related]
17. Primary myelofibrosis with thrombophilia as first symptom combined with thalassemia and Gilbert syndrome: A case report.
Wufuer G; Wufuer K; Ba T; Cui T; Tao L; Fu L; Mao M; Duan MH
World J Clin Cases; 2022 May; 10(13):4161-4170. PubMed ID: 35665102
[TBL] [Abstract][Full Text] [Related]
18. TNF-α is a predictive marker in distinguishing myeloproliferative neoplasm and idiopathic erythrocytosis/thrombocytosis: development and validation of a non-invasive diagnostic model.
Wang Z; Mei Y; Yang Z; Gao Q; Xu H; Han Z; Hong Z
Front Oncol; 2024; 14():1369346. PubMed ID: 38585007
[TBL] [Abstract][Full Text] [Related]
19. Enkurin: A novel marker for myeloproliferative neoplasms from platelet, megakaryocyte, and whole blood specimens.
Mosale Seetharam S; Liu Y; Wu J; Fechter L; Murugesan K; Maecker H; Gotlib J; Zehnder J; Paulmurugan R; Krishnan A
bioRxiv; 2023 Jan; ():. PubMed ID: 36712071
[TBL] [Abstract][Full Text] [Related]
20. Mathematical modelling, selection, and hierarchical inference to determine the minimal dose in IFNα therapy against Myeloproliferative Neoplasms.
Hermange G; Vainchenker W; Plo I; Cournède PH
Math Med Biol; 2024 Jun; ():. PubMed ID: 38875109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
